in vitro data (1.0L plasma perfusion)
Plasma flow rate : 30mL/min
Discard flow rate : 6mL/min

in vitro data (1.0L plasma perfusion)
Plasma flow rate : 30mL/min
Discard flow rate : 6mL/min

in vivo data
Blood flow rate : 100mL/min
Plasma flow rate : 25mL/min
Discard flow rate : 2.5mL/min
(Data from Shinseikan Daiichi Hospital, Japan)

in vivo data
Blood flow rate : 100mL/min
Plasma flow rate : 25mL/min
Discard flow rate : 2.5mL/min
(Data from Shinseikan Daiichi Hospital, Japan)

in vivo data
Blood flow rate : 100mL/min
Plasma flow rate : 25mL/min
Discard flow rate : 2.5mL/min
Treated plasma volume : 2.5L
(Data from Shinseikan Daiichi Hospital, Japan)

Cascadeflo EC is used as a plasma component separator in double filtration plasmapheresis in combination with a plasma separator (Plasmaflo OP) for selective extracorporeal plasma therapy.

Julius et al.

Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration.

J Clin Apher. 22:215-23, 2007.

Julius et al.

Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.

Int J Artif Organs. 25:1180-8, 2002.

Klingel et al.

From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis.

Ther Apher Dial. 7:350-8, 2003.

Klingel et al.

Lipidfiltration - safe and effective methodology to perform lipid-apheresis.

Transfusion and Apheresis Science. 30:245-254, 2004.

Taniguchi et al.

Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C.

Transplantation. 81:1747-9, 2006.

Fujiwara et al.

Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load.

Hepatol Res. 37:701-10, 2007.

Yu et al.

A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.

J Clin Rheumatol. 13:193-8, 2007.

Julius et al.

Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration.

J Clin Apher. 22:215-23, 2007.

Kaneko et al.

Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C.

Hepatol Res. 40:1072-1081, 2010.

Fernández-Fuertes et al.

Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia.

Ther Apher Dial. 14:484-5, 2010.

Liu et al.

Successful treatment of patients with systemic lupus erythematosus complicated with autoimmune thyroid disease using double-filtration plasmapheresis: a retrospective study.

J Clin Apher. 26:174-80, 2011.

Hirai et al.

Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.

Transpl Int. 25:925-34, 2012.

Lumlertgul et al.

Double filtration plasmapheresis in different diseases in Thailand.

Ther Apher Dial. 17:99-116, 2013.

Leebmann et al.

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study.

Circulation. 128:2567-76, 2013.

Sugimoto et al.

Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.

Dig Dis. 31:434-9, 2013.